--- title: "Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting" type: "News" locale: "en" url: "https://longbridge.com/en/news/285770756.md" description: "Biocure Technology Inc. has announced the adoption of semi-annual financial reporting under Coordinated Blanket Order 51-933. This change exempts the company from filing quarterly interim financial statements, as it meets the eligibility criteria of being a venture issuer with annual revenues under $10 million. Biocure will not file interim financial statements for the period ending March 31, 2026, but will continue to submit audited annual financial statements and six-month interim reports. The company remains committed to timely disclosure of material changes as required by regulations." datetime: "2026-05-08T20:15:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285770756.md) - [en](https://longbridge.com/en/news/285770756.md) - [zh-HK](https://longbridge.com/zh-HK/news/285770756.md) --- # Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting (TheNewswire) Vancouver, B.C. – TheNewswire - May 8, 2026‐ Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the “Company” or “Biocure”) announces the adoption of semi-annual financial reporting.This news release is being filed pursuant to Coordinated Blanket Order51 – 933 Exemptions toPermit Semi-Annual Reporting for Certain Venture Issuers (“CBO51-933”). CBO 51-933 allows eligible venture issuers tovoluntarily move from a quarterly to a semi-annual financial reportingframework. Biocure’s fiscal year ends on December 31. Under theprovisions of CBO 51-933, Biocure will be exempt from the requirementsto file its three-month interim financial statements and associatedmanagement’s discussion and analysis (“MD&A”) as itmeets the eligibility criteria under CBO 51-933, which include being aventure issuer with annual revenues of less than $10 million andmaintaining a clean 12-month continuous disclosure record.Accordingly, Biocure will not be filing its interim financialstatements for the three-month period ending March 31, 2026 andassociated MD&A. Biocure will continue to file audited annual financialstatements (due within 120 days of December 31, 2026) and six-monthinterim financial reports (due within 60 days of June 30, 2026).Biocure remains committed to timely disclosure and will continue toreport all material changes and significant developments as requiredunder National Instrument 51-102 – Continuous DisclosureObligations. About Biocure Technology Inc. Biocure Technology Inc. is a Canadian mineral exploration companyengaged in the acquisition, exploration, and development of mineralproperties. The Company is focused on advancing its explorationprojects and evaluating additional resource opportunities. On Behalf of the Board, BIOCURE TECHNOLOGY INC. Yee Sing (Simon) Cheng, CEO simonchengnow@gmail.com This news release is being filedpursuant to Coordinated Blanket Order 51-933 Exemptions to PermitSemi-Annual Reporting for Certain Venture Issuers. Neither the Canadian SecuritiesExchange nor its Regulation Services Provider (as that term is definedin the policies of the Canadian Securities Exchange) acceptsresponsibility for the adequacy or accuracy of this release. FORWARD LOOKINGSTATEMENTS Statements in this news releasewhich are not purely historical are forward-looking statements,including any statements regarding beliefs, plans, expectations, orintentions regarding the future. Forward looking statements in thisnews release include, but are not limited to, statements regardingthe Company’s adoption ofsemi-annual financial reporting; the Company’s intention not to fileinterim financial reports for the three-month and nine-month interimperiods; the Company’s ongoing eligibility to rely on CBO 51-933;and the Company’s commitment and intention to file the auditedannual financial statements and the six-month interim financialreports as well as report all material changes and significantdevelopments as required under National Instrument 51-102 –Continuous Disclosure Obligations. Risks and uncertainties includechanges to the Company’sfinancial or regulatory standing; changes to or revocation of CBO51-933; and changes insecurities legislation or the policies of the Canadian SecuritiesExchange; that economic,competitive, governmental, geopolitical, environmental andtechnological factors may affect the Company’s operations, markets,products and prices; our specific plans and timing drilling, fieldwork and other plans may change; that the Company may not have accessto or be able to develop any minerals because of cost factors, type ofterrain, or availability of equipment and technology; and we may alsonot raise sufficient funds to carry out or complete our plans. Laborshortages, inflationary pressures, rising interest rates, the globalfinancial climate and international conflicts are some additionalfactors that are affecting current economic conditions and increasingeconomic uncertainty, which may impact the Company’s operatingperformance, financial position, and prospects. Collectively, thepotential impacts of this economic environment pose risks that arecurrently indescribable and immeasurable. No assurance can be giventhat any of the events anticipated by the forward-looking statementswill occur or, if they do occur, what benefits the Company will obtainfrom them. Readers are cautioned that forward-looking statements arenot guarantees of future performance or events and, accordingly, arecautioned not to put undue reliance on forward-looking statements dueto the inherent uncertainty of such statements. Additional riskfactors are discussed in the section entitled “Risk Factors” inthe Company’s MD&A for its recently completed fiscal period,which is available under the Company’s SEDAR+ profileat www.sedarplus.ca. Except asrequired by law, the Company will not update or revise theseforward-looking statements after the date of this document or torevise them to reflect the occurrence of future unanticipatedevents. Copyright (c) 2026 TheNewswire - All rights reserved. ### Related Stocks - [CUBT.US](https://longbridge.com/en/quote/CUBT.US.md) - [CURE.US](https://longbridge.com/en/quote/CURE.US.md) ## Related News & Research - [Molina Healthcare Inc. Stock Outperforms Competitors Despite Losses On The Day](https://longbridge.com/en/news/287122959.md) - [Molina Healthcare Shareholders Approve Governance and Bylaw Changes](https://longbridge.com/en/news/285956721.md) - [Centric Wealth Management Cuts Stock Position in Molina Healthcare, Inc $MOH](https://longbridge.com/en/news/285907903.md) - [Curative Biotechnology Announces Canadian Patent Allowance | CUBT Stock News](https://longbridge.com/en/news/273523347.md) - [Molina Healthcare Unveils Long-Term Strategy at Investor Day](https://longbridge.com/en/news/285736447.md)